


## Moclobemide-d<sub>4</sub>

Cat. No.:	HY-B0534S1		
Molecular Formula:	C <sub>13</sub> H <sub>13</sub> D <sub>4</sub> ClN <sub>2</sub> O <sub>2</sub>		
Molecular Weight:	272.76		
Target:	Monoamine Oxidase		
Pathway:	Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (366.62 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	3.6662 mL	18.3311 mL	36.6623 mL	
5 mM	0.7332 mL	3.6662 mL	7.3325 mL	
10 mM	0.3666 mL	1.8331 mL	3.6662 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Moclobemide-d<sub>4</sub> is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC<sub>50</sub> of 6.061 μM for hMAO-A[1]. Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Nafiz Öncü Can, et al. Synthesis of New Hydrazone Derivatives for MAO Enzymes Inhibitory Activity. *Molecules.* 2017 Aug 20;22(8):1381.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA